Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Adv...

    2025-10-16

    Y-27632 Dihydrochloride: Elevating Cell Model Research with Selective ROCK Inhibition

    Principle Overview: Y-27632 Dihydrochloride and the Rho/ROCK Signaling Pathway

    Y-27632 dihydrochloride is a highly selective small-molecule inhibitor of Rho-associated protein kinases, specifically ROCK1 and ROCK2. With IC50 values of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, Y-27632 dihydrochloride offers over 200-fold selectivity compared to kinases such as PKC, MLCK, and PAK. By targeting the catalytic domains of these kinases, this compound disrupts Rho-mediated stress fiber formation, modulates cell cycle progression (notably G1 to S phase), and interferes with cytokinesis. These actions underpin its utility in modulating cytoskeletal dynamics, enhancing stem cell viability, and suppressing tumor invasion and metastasis.
    Y-27632 dihydrochloride is cell-permeable and highly soluble in DMSO, ethanol, and water, making it suitable for a wide range of in vitro and in vivo applications. Its precision as a selective ROCK1 and ROCK2 inhibitor has transformed workflows in cancer research, regenerative medicine, and advanced 3D culture systems.

    Step-by-Step Experimental Workflow: Integrating Y-27632 into Organoid and Cell Culture Protocols

    1. Preparation of Stock Solutions

    • Dissolve Y-27632 dihydrochloride at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Ultrasound or warming to 37°C facilitates dissolution.
    • Filter-sterilize and aliquot for storage at -20°C. Avoid repeated freeze-thaw cycles to maintain activity.

    2. Application in Organoid Culture

    • Add Y-27632 at a final concentration of 10 μM to organoid initiation medium to enhance single-cell survival and promote colony formation.
    • Maintain the compound in culture medium for the first 24–72 hours post-dissociation or passaging, then replace with ROCK inhibitor-free medium for downstream assays.

    3. Stem Cell Expansion

    • For human pluripotent stem cell (hPSC) or induced pluripotent stem cell (iPSC) cultures, supplement with Y-27632 during thawing, passaging, and single-cell cloning to improve cell viability and reduce apoptosis.
    • Recommended concentration: 10–20 μM for 24 hours post-dissociation.

    4. Cell Proliferation and Cytotoxicity Assays

    • Include Y-27632 dihydrochloride in cell proliferation assays to evaluate the impact of Rho/ROCK signaling on cell cycle dynamics, especially in cancer cell lines and primary cultures.
    • Monitor for concentration-dependent effects; published data shows reduced proliferation of prostatic smooth muscle cells in vitro with increasing Y-27632 levels.

    5. In Vivo Tumor Invasion and Metastasis Models

    • Administer Y-27632 systemically or via local injection in mouse models to investigate its role in reducing pathological tumor structures and suppressing metastasis.
    • Monitor for decreased tumor invasion correlated with ROCK pathway inhibition.

    Protocol Enhancement: Case Study in Breast Cancer Organoids

    A prominent application was demonstrated in the establishment of patient-derived breast cancer organoids from adenomyoepithelioma (AME). Here, Y-27632 was critical for single-cell viability and successful 3D culture formation, providing a disease-relevant model for drug sensitivity testing and molecular analysis. The organoids retained the DNA signature of the parental tumor, confirming fidelity and utility for translational research.

    Advanced Applications and Comparative Advantages

    1. Enhancing Stem Cell Viability and Clonogenicity

    Y-27632 dihydrochloride is widely recognized for its ability to suppress dissociation-induced apoptosis (anoikis) in stem cell cultures. When included during single-cell passaging of hPSCs, survival rates can increase by up to 5-fold, dramatically improving colony-forming efficiency. This property is indispensable for workflows involving gene editing, reprogramming, or clonal expansion.

    2. Modeling Tumor Invasion and Metastasis

    By inhibiting Rho/ROCK-driven cytoskeletal remodeling, Y-27632 impairs cancer cell motility and invasion in both 2D and 3D systems. In vivo, its administration has been shown to reduce metastatic burden and pathological structures in mouse tumor models. These effects position Y-27632 as a unique tool for dissecting the molecular underpinnings of tumor spread and for preclinical drug screening.

    3. Precision in Cytoskeletal and Cytokinesis Studies

    Unlike less selective kinase inhibitors, Y-27632 dihydrochloride exerts minimal off-target effects on kinases such as PKC or MLCK, allowing for clear attribution of observed phenotypes to ROCK pathway modulation. This selectivity is particularly valuable for high-content imaging or mechanobiology studies where cytoskeletal dynamics are in focus.

    4. Complementing and Extending Prior Research

    Recent reviews, such as "Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Stem Cell and Cancer Invasion Studies", reinforce the compound’s role in bridging stem cell biology and cancer research. Comparative insights from "Y-27632 Dihydrochloride: Advanced ROCK Inhibition in Cancer Communication" highlight its additional utility in modulating extracellular vesicle release, suggesting synergistic strategies for tumor microenvironment research. Meanwhile, the mechanistic depth explored in "Unlocking Neuroepigenetic and Cancer Invasion Pathways" complements the cytoskeletal focus by mapping downstream transcriptional impacts, underscoring the broad translational relevance of ROCK pathway inhibition.

    Troubleshooting and Optimization Tips for Y-27632 Workflows

    • Solubility Issues: Should precipitation occur, gently warm the solution to 37°C or use an ultrasonic bath. Prepare aliquots to avoid repeated freeze-thaw cycles, and store solids desiccated at 4°C or below.
    • Cytotoxicity at High Concentrations: While Y-27632 is well-tolerated up to 20 μM in most cell types, some primary cultures may exhibit sensitivity. Titrate concentrations and include vehicle controls to distinguish specific ROCK pathway effects.
    • Long-Term Storage: Avoid storing diluted solutions for extended periods. Prepare fresh working solutions weekly to ensure maximal activity.
    • Assay Interference: For downstream applications (e.g., drug sensitivity or signaling assays), remove Y-27632 after initial plating or passaging to prevent confounding effects on cell behavior.
    • Batch Consistency: Use the same lot number for longitudinal studies, as minor batch-to-batch variations in compound purity or solubility may affect results.

    Future Outlook: Y-27632 in Next-Generation Disease Modeling and Therapy

    The adoption of Y-27632 dihydrochloride as a cell-permeable ROCK inhibitor for cytoskeletal studies has already catalyzed advances in organoid technology, stem cell viability enhancement, and tumor invasion/metastasis suppression. As illustrated by the breast AME organoid study, the ability to reliably generate patient-derived models will accelerate personalized medicine and high-throughput drug screening. Looking forward, integration with CRISPR-based editing, single-cell omics, and engineered microenvironments is likely to expand the utility of Y-27632 in both discovery science and translational applications.

    With ongoing efforts to dissect the Rho/ROCK signaling pathway in cancer biology, regenerative medicine, and neuroepigenetics, Y-27632 dihydrochloride remains a pivotal enabler for experimental innovation. For researchers seeking reproducibility, selectivity, and scalability in their cell-based assays, Y-27632 dihydrochloride offers a robust foundation for the next generation of experimental workflows.